Moderna Stock

Moderna P/TBV

The Price to Tangible Book Value (P/TBV) of Moderna (MRNA) as of Aug 7, 2026 is 1.92. In the previous year, Price to Tangible Book Value (P/TBV) was 1.53 — a change of 25.72% (higher).

P/TBV

1.92

YoY

25.72%

Last updated:

Price to Tangible Book Value (P/TBV) of Moderna is 2026 1.92 . Price to Tangible Book Value (P/TBV) of Moderna was 2025 1.53 . It decreases by 25.72% higher compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

Price to Tangible Book Value (P/TBV) of Moderna is 1.92 in 2026.

Price to Tangible Book Value (P/TBV) of Moderna changed from 1.53 to 1.92, representing a 25.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Moderna since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Moderna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Moderna

All Key Metrics — Moderna